The company revealed the findings at a London medical conference, confirming that the treatment was well tolerated in the study. By targeting both intracellular and extracellular tau—a protein linked to neuronal health in the central nervous system—the therapy demonstrated sustained efficacy during the observation period. The U.S. Food and Drug Administration granted investigational new drug clearance for the candidate in June, paving the way for upcoming trials.

Chief Executive Alfred Sandrock stated that the data reinforces the pharmacology and durability observed in earlier testing. Voyager remains focused on the potential of tau as a therapeutic target for neurodegenerative decline. Investors responded to the announcement with a 3.3% uptick in premarket trading, pushing shares to $3.55, a modest recovery after the stock’s 12% decline earlier this year.